user-generated· earnings
Pharmaceutical companies' U.S. revenue growth slows by 5% in 2027
Trump's most favored nation policy and potential legislative caps on drug prices would directly reduce revenue for U.S. pharma companies. The policy aims to align prices with lower international rates, likely leading to a measurable slowdown in revenue growth.
earnings · Prediction Market
- Implied probability (Yes)
- 75%
More earnings markets
- Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
- Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
- Titleist sells more clubs than Callaway in 2026 — 72% Yes
- Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
- Lime achieves profitability within 12 months post-IPO — 55% Yes
- SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
- Flexjet stock rises 15% by Q4-2027 on fuel cost advantage — 70% Yes
- Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes
Loading…